Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Narrative (Details)

v3.23.2
Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 19, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2023
site
May 01, 2021
periods
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Renewal options | periods             4
Renewal period (in years)             1 year
Agreement term (in days)             90 days
License agreement term (in days) 10 days            
General and administrative expense   $ 9,937 $ 6,306 $ 18,235 $ 14,130    
Number Of Sites | site           12  
License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
General and administrative expense   $ 500   $ 700      
License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront license fee $ 50            
License or royalty net revenue percentage 3.00%            
Royalty expense $ 250            
License Agreement | Phase 3              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Additional payment of fee 900            
License Agreement | New Drug Application              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Additional payment of fee $ 1,000